Maintenance Rituximab after high-dose therapy and autologous stem cell transplantation in mantle cell lymphoma
Abstract: Mantle cell lymphoma (MCL) is an aggressive B cell lymphoma characterized by early dissemination and an unfavorable clinical course. Treatment with conventional chemotherapy resulted in unsatisfactory outcomes and a median survival of less than 3 years after diagnosis of MCL [1]. In recent...
Enregistré dans:
| Auteurs principaux: | , |
|---|---|
| Format: | Article (Journal) |
| Langue: | anglais |
| Publié: |
November 2017
|
| In: |
Biology of blood and marrow transplantation
Year: 2017, Volume: 23, Numéro: 11, Pages: 1811-1812 |
| ISSN: | 1523-6536 |
| DOI: | 10.1016/j.bbmt.2017.09.008 |
| Accès en ligne: | Verlag, Volltext: http://dx.doi.org/10.1016/j.bbmt.2017.09.008 Verlag, Volltext: http://www.bbmt.org/article/S1083-8791(17)30716-4/abstract 
|
| Notes sur l'auteur: | Tobias Roider, Sascha Dietrich |
| Résumé: | Abstract: Mantle cell lymphoma (MCL) is an aggressive B cell lymphoma characterized by early dissemination and an unfavorable clinical course. Treatment with conventional chemotherapy resulted in unsatisfactory outcomes and a median survival of less than 3 years after diagnosis of MCL [1]. In recent years, the prognosis of patients with MCL has improved considerably, and the refinement of dose-intensified approaches such as autologous stem-cell transplantation (ASCT) has contributed significantly to this development. |
|---|---|
| Description: | Gesehen am 10.04.2018 |
| Description matérielle: | Online Resource |
| ISSN: | 1523-6536 |
| DOI: | 10.1016/j.bbmt.2017.09.008 |